First Trust Advisors LP Regenxbio Inc. Transaction History

First Trust Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$18.08 - $24.55 $262,901 - $356,981	-14,541 Reduced 14.71%	84,305 $1.59 Million
Q4 2022 Feb 09, 2023	BUY	$20.4 - $24.73 $2.02 Million - $2.44 Million	98,846 New	98,846 $2.24 Million
Q4 2021 Feb 08, 2022	SELL	$30.19 - $40.28 $1.3 Million - $1.73 Million	-43,067 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$29.09 - $45.68 $753,663 - $1.18 Million	25,908 Added 150.99%	43,067 $1.81 Million
Q2 2021 Aug 16, 2021	SELL	$32.46 - $40.48 $2.07 Million - $2.58 Million	-63,648 Reduced 78.77%	17,159 $667,000
Q1 2021 May 14, 2021	BUY	$33.61 - $49.95 $2.72 Million - $4.04 Million	80,807 New	80,807 $2.76 Million
Q3 2019 Nov 04, 2019	SELL	$31.84 - $50.88 $1.77 Million - $2.82 Million	-55,504 Closed	0 $0
Q2 2019 Jul 30, 2019	SELL	$42.0 - $59.29 $44,520 - $62,847	-1,060 Reduced 1.87%	55,504 $2.85 Million
Q1 2019 May 09, 2019	SELL	$40.82 - $62.45 $299,210 - $457,758	-7,330 Reduced 11.47%	56,564 $3.24 Million
Q4 2018 Feb 07, 2019	BUY	$39.11 - $75.15 $2.5 Million - $4.8 Million	63,894 New	63,894 $2.68 Million

196

43M

104K

478K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $329M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.